Related Experiment Video

Updated: Jul 6, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Glucocorticoid treatment inhibits annexin-1 expression in rheumatoid arthritis CD4+ T cells

F D'Acquisto1, N Paschalidis, K Raza

  • 1The William Harvey Research Institute, Centre for Biochemical Pharmacology, Barts and The London, Queen Mary School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK. F.Dacquisto@qmul.ac.uk

Rheumatology (Oxford, England)
|April 9, 2008
PubMed
Abstract

Insights

Glucocorticoids suppress Annexin-1 (Anx-A1) expression in T cells, impacting adaptive immune responses. This suggests Anx-A1 may be a therapeutic target for autoimmune diseases like rheumatoid arthritis.

Area of Science:

  • Immunology
  • Molecular Biology
  • Rheumatology

Background:

  • Annexin-1 (Anx-A1) is crucial for T-cell activation and highly expressed in rheumatoid arthritis (RA) T cells.
  • Glucocorticoids (GCs) are potent anti-inflammatory drugs used in treating autoimmune diseases.

Purpose of the Study:

  • To investigate the impact of GCs on Anx-A1 expression in T cells.
  • To explore the role of Anx-A1 in GC-mediated regulation of T-cell responses.

Main Methods:

  • Human T cells were treated with dexamethasone (Dex) in vitro, followed by real-time PCR and western blotting.
  • Anx-A1 levels were measured in T cells from RA patients before and after steroid treatment in vivo.

Main Results:

  • Dexamethasone significantly reduced Anx-A1 expression in T cells in a time-dependent manner.
  • Reduced Anx-A1 impaired T-cell IL-2 production, which was restored by adding recombinant Anx-A1.
  • Steroid treatment decreased Anx-A1 levels in T cells from RA patients.

Conclusions:

  • GCs suppress Anx-A1 expression in T cells both in vitro and in vivo.
  • This study reveals a novel mechanism for steroid regulation of adaptive immunity.
  • Anx-A1 emerges as a potential therapeutic target for autoimmune diseases.

More Related Videos

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Published on: January 31, 2020

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...